Results of the second phase-3 study of Lasmiditan in migraine (SPARTAN) are due in 2H17. SPARTAN has the same design as SAMURAI except that SPARTAN added the 50mg dose and includes ex-US trial sites. Both trials have an SPA.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.